Topic: Oral Cavity/Oropharyngeal Cancer: Overview of the Current Research Guest Editor/Editor: Antonia Kolokythas, Department of Oral and Maxillofacial Surgery, University of Illinois at Chicago, Chicago, USA.
Literature Reviews
e1
Animal Models to Study the Mutational Landscape for Oral Cavity
and Oropharyngeal Cancers
Michael T. Spiotto, Matthew Pytynia, Gene-Fu F. Liu, Mark C.
Ranck, Ryan Widau
Objectives: Cancer is likely caused by alterations in gene structure or expression.
Recently, next generation sequencing has documented mutations in 106 head and
neck squamous cell cancer genomes, suggesting several new candidate genes.
However, it remains difficult to determine which mutations directly contributed
to cancer. Here, summarize the animal models which have already validated and
may test cancer causing mutations identified by next generation sequencing
approaches.
Material and Methods: We reviewed the existing literature on genetically engineered mouse
models and next generation sequencing (NGS), as it relates to animal models of
squamous cell cancers of the head and neck (HNSCC) in PubMed.
Results: NSG has identified an average of 19 to 130 distinct mutations per HNSCC
specimen. While many mutations likely had biological significance, it
remains unclear which mutations were essential to, or "drive,"
carcinogenesis. In contrast, "passenger" mutations also exist that
provide no selection advantage. The genes identified by NGS included
p53, RAS, Human Papillomavirus oncogenes, as well as novel genes such as
Notch1, Dicer and SYNE1,2. Animal models of HNSCC have already validated
some of these common gene mutations identified by NGS.
Conclusions: The advent of next generation sequencing will provide new leads to the
genetic changes occurring in squamous cell cancers of the head and neck. Animal
models will enable us to validate these new leads in order to better elucidate
the biology of squamous cell cancers of the head and neck.
Objectives: Head and neck/oral cancer, predominantly head and neck squamous cell
carcinoma (HNSCC), is the sixth most common cancer in the world. While
substantial advances have been made to define the genomic alterations
associated with head and neck/oral cancer, most studies are focused on
protein coding genes. The aim of this article is to review the current
literature on identified genomic aberrations of non-coding genes (e.g.,
microRNA) in head and neck/oral cancer (HNOC), and their contribution to
the initiation and progression of HNOC.
Material and Methods: A comprehensive review of the available literature relevant to microRNA
deregulation in HNSCC/HNOC, was undertaken using PubMed, Medline, Scholar Google
and Scopus. Keywords for the search were: microRNA and oral cancer, microRNA and
squamous cell carcinoma, microRNA deregulation and oral cancer, microRNA and
carcinogenesis in the head and neck/oral cavity. Only full length articles in
the English language were included.
Results: We recently identified a panel of microRNA deregulations that were
consistently observed in HNSCC [Chen et al., Oral Oncol.
2012;48(8):686-91], including 7 consistently up-regulated microRNAs
(miR-21, miR-7, miR-155, miR-130b, miR-223, miR-34b), and 4 consistently
down-regulated microRNAs (miR-100, miR-99a, miR-125b, miR-375). In this
review, we will first provide an overview on microRNA and HNSCC. We will
then provide a comprehensive review on the roles of microRNA
deregulations in HNSCC. The functional significance of the identified
HNSCC-associated microRNAs and a number of other relevant microRNAs
(e.g., miR-138, miR-98, miR-137, miR-193a and miR-218) will be discussed
in detail.
Objectives: The aim of this study was to detect the presence of myofibroblasts and
transforming growth factor-beta1 in fibrous and ossifying-fibrous epulis
and their possible contribution to the collagenous connective tissue
formation. The correlation between the myofibroblasts and the degree of
inflammatory infiltration was also examined.
Material and Methods: The presence of myofibroblasts as well as transforming growth
factor-beta1 was examined in twenty cases of fibrous epulis and 22 ossifying
fibrous epulis, using immunohistochemistry.
Results: Myofibroblasts positive for alpha smooth muscle actin and vimentin but
negative to desmin were found in 20% and 45% in fibrous epulis and ossifying
fibrous epulis, respectively. Myofibroblasts were distributed in areas with and
without inflammatory infiltration and their presence in inflammatory areas was
not related with the degree of inflammatory infiltration. A percentage of 21 -
60% of fibroblasts and chronic inflammatory cells expressed transforming growth
factor-beta1 in all cases.
Conclusions: These data suggest that transforming growth factor-beta1 and
myofibroblasts contribute to the formation of collagenous connective tissue in
fibrous epulis and ossifying fibrous epulis. Myofibroblasts are mainly presented
in ossifying fibrous epulis than in fibrous epulis. It seems to be no
relationship between the presence of myofibroblasts and the degree of
inflammatory infiltration of the lesions.
Background: The aim of the present article is to report a case of
ameloblastic carcinoma and use a marker alpha smooth muscle actin as a
tool to differentiate cases of ameloblastic carcinoma from that of
ameloblastoma.
Methods: Case study reporting a case of ameloblastic carcinoma (AC)
with expression of alpha smooth muscle actin (alpha-SMA) as a marker for
emergence of stromal myofibroblasts. The expression of myofibroblasts was also
compared with that of ameloblastoma.
Results: Difference between the two lesions in the pattern of
expression of alpha smooth muscle actin was also observed. There was increase in
the number of myofibroblasts in the stroma of AC while in ameloblastoma, it was
comparatively less. Secondly, few areas of the carcinomatous ameloblastic island
also exhibited a mild positivity towards alpha smooth muscle actin.
Conclusions: Increase in number of stromal myofibroblast may be
taken as a predictor for carcinomatous transformation. Further studies with
greater sample size can validate the use of alpha-SMA as a marker to
differentiate ameloblastic carcinoma from ameloblastoma.
Background: Giant cell fibroma is a type of fibrous tumour of the oral mucosa which
rarely affects children under the age of 10. The purpose of this paper was
to contribute two clinically and histologically documented cases of giant cell
fibroma in the free gingiva of a 7 and 6 year old boys.
Methods: Both nodules were presented in the mandibular anterior region. In the
differential diagnosis several fibrous hyperplastic lesions were considered such
as traumatic fibroma, papilloma, peripheral ossifying fibroma, peripheral
odontogenic fibroma, giant cell fibroma and odontogenic hamartoma.
Results: The lesions were removed and the histological examination revealed
fibrocollagenous connective tissue with the presence of stellate giant cells
which confirmed the diagnosis of giant cell fibroma.
Conclusions: Dentists should be aware of the existence of giant cell fibroma in
children, which must be included in the differential diagnosis of nodular
lesions of the gingiva and adequately diagnosed and treated by removal and
histopathological examination.